Drug Database
Back to search

Netherlands· NL-2c3bbad295c8

Aucatzyl 410 × 106 cellen dispersie voor infusie

A obecabtagene autoleucel product containing obecabtageen autoleucel, registered in Netherlands by Autolus GmbH. The same ATC class is registered in 7 of our 19 countries.

ATC L01XL12

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedAucatzyl 410 × 106 cellen dispersie v…ATCL01XL12REGISTER NO.NL-2c3bbad295c8PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about obecabtageen autoleucelAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Obecabtagene autoleucel is registered in 7 of 19 countries.

Countries holding a registration under ATC L01XL12 (obecabtagene autoleucel), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 4 of them publish a price we can compare per daily dose
Search obecabtagene autoleucel products by name

Obecabtagene autoleucel · ATC L01XL12

7 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
OBECABTAGEEN AUTOLEUCEL
Manufacturer
Autolus GmbH
Country
Netherlands (NL)
ATC code
L01XL12
ATC class
Obecabtagene autoleucel
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/25/1951

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Obecabtagene autoleucel in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All obecabtagene autoleucel products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Aucatzyl
  • Liechtenstein · Aucatzyl
  • Norway · Aucatzyl

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4f9037fe-4183-4364-abda-eeb4d03f7a77
GET /v1/drugs/4f9037fe-4183-4364-abda-eeb4d03f7a77?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Dispersie voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/aucatzyl-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Obecabtagene autoleucel",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp133008",
  "excipients": [
    "DIMETHYLSULFOXIDE",
    "DINATRIUMWATERSTOFFOSFAAT 0-WATER (E 339)",
    "ETHYLEENDIAMINETETRAAZIJNZUUR",
    "HUMAAN ALBUMINE",
    "KALIUMCHLORIDE (E 508)",
    "KALIUMDIWATERSTOFFOSFAAT 0-WATER (E 340)",
    "NATRIUMCHLORIDE",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "OBECABTAGEEN AUTOLEUCEL"
  ],
  "leaflet_url": null,
  "authorised_at": "2025/07/17",
  "procedure_number": "EMEA/H/C/005907",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/25/1951",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about obecabtagene autoleucel.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console